Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC
Clinical trial NCT05027100 · UNKNOWN
Trial details
- NCT number
- NCT05027100
- Sponsor
- Haibo Zhang
- Status
- UNKNOWN
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-30
- Primary completion
- 2022-12-01
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.